A Randomized Controlled Study on the Effect of MRJPs on Improving Ovarian Function and Endometrial Receptivity

NCT07246733 | Recruiting DMC

• 1 other identifier: KY-2025-121
• Study Type: interventional
• Target: 66
• Locations: 1 country
• Sites: 1

Brief Summary

This study will assess the effects of the rose tablet candies produced by MRJPs on the subjects, evaluate the role of MRJPs in the ovarian function and endometrial receptivity of women, reveal the potential application value of MRJPs in reproductive health, and determine its safety and effectiveness.

Conditions

Diminished Ovarian Reserve (DOR); Thin Endometrium

Keywords

Ovarian reserve; Endometrial receptivity; Major Royal Jelly Proteins（MRJPs）; Reproductive health

Outcome Measures

Primary Outcomes (1)

• Anti-Müllerian hormone

  Ovarian function testing indicator

  From enrollment to the end of treatment at 1 month

Secondary Outcomes (4)

• Sex hormone levels

  From enrollment to the end of treatment at 1 month

• Endometrial receptivity

  From enrollment to the end of treatment at 1 month

• Sex hormone levels

  From enrollment to the end of treatment at 1 month

• Sex hormone levels

  From enrollment to the end of treatment at 1 month

Study Arms (2)

Experimental group

EXPERIMENTAL

Oral MRJPs Candy (500 mg per tablet, containing 70% MRJPs freeze-dried powder + 20% sodium cellulose + 10% microcrystalline cellulose, with an appropriate amount of arabinose), taken twice a day, 1 tablet each time, for a total of 1 menstrual cycle

Dietary Supplement: Oral MRJPs Candy

Control group

PLACEBO COMPARATOR

Oral placebo candy (500 mg per tablet, containing 70% whey protein powder + 20% sodium cellulose + 10% microcrystalline cellulose, with appropriate amount of arabinose), taken twice a day, 1 tablet each time, for a total of 1 menstrual cycle in the control group.

Dietary Supplement: Oral placebo candy

Interventions

Oral MRJPs Candy DIETARY_SUPPLEMENT

500 mg per tablet, containing 70% MRJPs freeze-dried powder + 20% sodium cellulose + 10% microcrystalline cellulose, with an appropriate amount of arabinose, taken twice a day, 1 tablet each time, for a total of 1 menstrual cycle in the control group.

Experimental group

Oral placebo candy DIETARY_SUPPLEMENT

500 mg per tablet, containing 70% whey protein powder + 20% sodium cellulose + 10% microcrystalline cellulose, with appropriate amount of arabinose, taken twice a day, 1 tablet each time, for a total of 1 menstrual cycle in the control group.

Control group

Eligibility Criteria

• Age: 20 Years - 45 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Fertile women, aged 20 to 45 years old, with regular and normal menstrual cycles.

You may not qualify if:

• ① Allergic to royal jelly or its components; ② Suffering from severe chronic diseases or endocrine system disorders; ③ Pregnant or breastfeeding; ④ Undergoing hormone replacement therapy (HRT) within the last month

Sponsors & Collaborators

• The Fourth Affiliated Hospital of Zhejiang University School of Medicine: lead

Study Sites (1)

The Fourth Affiliated Hospital of Zhejiang University School of Medicine

Yiwu, Zhejiang, 322000, China

RECRUITING

Central Study Contacts

Xiaolin Wu

CONTACT

+86-579-19548878600; daringwxl@163.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 3, 2025
• First Posted: November 24, 2025
• Study Start: July 1, 2025
• Primary Completion (Estimated): June 30, 2028
• Study Completion (Estimated): July 31, 2028
• Last Updated: November 24, 2025

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)